智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理

Core Viewpoint - The company, Zhifei Biological, has received a clinical trial application acceptance notice for its modified Ankara vaccine for monkeypox, marking a significant breakthrough in its vaccine development efforts [1] Group 1: Clinical Trial Acceptance - Zhifei Longkema, a wholly-owned subsidiary of Zhifei Biological, has developed a modified Ankara vaccine for monkeypox, which has been accepted for clinical trial by the National Medical Products Administration [1] - The acceptance number for the clinical trial application is CXSL2501083, allowing the company to proceed with trials if no negative feedback is received within 60 days [1] Group 2: Vaccine Technology and Safety - The vaccine utilizes a live attenuated vaccine technology route, employing the modified Ankara strain, which cannot effectively replicate in human cells, ensuring high safety [1] - This development is seen as a key achievement in the company's focus on innovative technology and enhancing core capabilities [1] Group 3: Strategic Implications - The acceptance of the clinical trial application is expected to enhance the company's long-term stable development and improve China's independent innovation capabilities in major infectious disease prevention [1] - Successful progress in this project will diversify the company's vaccine offerings, improve its product portfolio, and strengthen its market position [1]